Recent Press Releases

Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech

Shire to Acquire NPS Pharma as Further Step in Building a Leading Biotech Transaction valued at $5.2 billion Enhances growth profile Dublin, Ireland and Bedminster, NJ – January 11, 2015...

Record number of medicines for rare diseases recommended for approval in 2014

Number of medicines with new active substances continues to increase In 2014, the European Medicines Agency (EMA) recommended the highest number of orphan designated medicines for marketing...

FDA approves anti-clotting drug Savaysa

Drug approved to treat atrial fibrillation, deep vein thrombosis, and pulmonary embolism The U.S. Food and Drug Administration today approved the anti-clotting drug Savaysa (edoxaban tablets) to...

ABBVIE ISSUES STRONG OUTLOOK FOR 2015

- EXPECTS ADJUSTED EARNINGS PER SHARE OF $4.25 TO $4.45 (GAAP EPS OF $3.99 TO $4.19); GUIDANCE TO BE FURTHER REFINED AS HCV LAUNCH PROGRESSES - GUIDANCE MIDPOINT REFLECTS ADJUSTED EPS GROWTH OF MORE...

Amgen To Present At The 33rd Annual J.P. Morgan Healthcare Conference

THOUSAND OAKS, Calif., Jan.

ATHENA data publication reinforces new interim guidance from medical societies on use of HPV as first-line test in cervical cancer screening

SGO, ASCCP leverage newly published end-of-study data to support option of HPV primary screening for women 25 and older

INDIANAPOLIS

Actavis Confirms Appeals Court Grants Expedited Appeal of Ruling Requiring Continued Distribution of NAMENDA® IR

DUBLIN, Jan. 6, 2015 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that the U.S. Court of Appeals for the Second Circuit granted the Company's motion to expedite its appeal of a lower...

GW Pharmaceuticals and Otsuka Announce Results in First of Three Sativex(R) Phase 3 Cancer Pain Trials

- Primary endpoint did not show a statistically significant difference for Sativex compared with placebo in reducing pain - Conference call and webcast with GW management scheduled at 8:00 a.m. EST,...

Lilly Provides Update on Strategy and Announces 2015 Financial Guidance

- The company describes refinements to its innovation-based strategy, including greater focus on core therapeutic areas and key geographies.

Director General of EFPIA: "Pan-European HTA necessary"

London, January 5 2015: Richard Bergström, Director General, EFPIA argued passionately in favour of the homogenisation of European HTA bodies and regulation, during a recent interview with Paul...

23andMe and Genentech to Analyze Genomic Data for Parkinson's Disease

New program will support the identification of novel drug targets to treat Parkinson's disease

MOUNTAIN VIEW, Calif.,

Cooper University Health Care Advances Patient Services with Comcast Business

Ethernet Network Supports Electronic Medical Records, Patient Portal, Video Collaboration and Secure Ethernet @Home Connections for Radiologists to Review Patient Imaging Outside of Work

Onco360 Chosen by Bayer as Limited Distribution Pharmacy Provider

Company's Comprehensive Drug Portfolio Further Expands with Addition of Two Leading Products NEW YORK, Jan 05, 2015 (BUSINESS WIRE) -- Onco360, one of the nation's largest independent...

Mylan Launches Generic Diovan(R) Tablets

PITTSBURGH, Jan. 5, 2015 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced the U.S. launch of its Valsartan Tablets USP 40 mg, 80 mg, 160 mg, and 320 mg, which is the generic version of...

The cost of nab-paclitaxel is not justified by its limited benefit, says NICE in draft guidance

The cost of nab-paclitaxel is not justified by its limited benefit, says NICE in draft guidance NICE has published draft guidance which recommends that nab-paclitaxel given with gemcitabine should...

Qualcomm announces strategic collaboration with Novartis to optimize global clinical trials

--Novartis selects Qualcomm Life and its 2net technology to digitize its clinical trials--

SAN DIEGO, Jan.

Lilly to Present at J.P. Morgan Healthcare Conference

INDIANAPOLIS, Jan.

Lilly Announces Promotion of Darren J. Carroll to Senior Vice President of Corporate Business Development

Lilly plans to increase its business development activities to support its external innovation strategy

INDIANAPOLIS,